Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn:
“The Symposium on Pancreatic Ductal Adenocarcinoma, organized by the Fundación Ramón Areces, took place in Madrid on September 17, 2025. The event gathered leading experts to discuss the biology of PDAC and the development of new therapeutic strategies, with a strong focus on KRAS inhibitors.
For those who could not attend, the full set of presentations is now available in this video.
Program:
Session III – Chair: Andrés Muñoz Martín
Peter Bailey (Botton-Champalimaud Foundation Pancreatic Cancer Centre, Lisbon) – Genetic and non-genetic mechanisms driving progression and resistance to therapy in PDAC
Dieter Saur (DKFZ German Cancer Research Center & Technical University of Munich) – Tumor–host interactions in pancreatic cancer
Nuria Malats (CNIO – Spanish National Cancer Research Centre, Madrid) – Metabolic crossroads: exploring the diabetes–obesity–pancreatic cancer axis
Nelson Dusetti (CRCM – Centre de Recherche en Cancérologie de Marseille & Institut Paoli-Calmettes, Marseille) – Exploring the molecular routes of resistance in pancreatic cancer
Session IV – Chair: Alfredo Carrato Mena Carrato
Silvestre Vicent Cambra (CIMA, University of Navarra) – Combination strategies to potentiate the effect of KRAS inhibitors
Laura Soucek (VHIO, Barcelona) – The long journey to inhibit an “undruggable” target in pancreatic cancer and beyond
Teresa Macarulla (Vall d’Hebron University Hospital & VHIO, Barcelona) – State of the art and new therapeutic options in advanced pancreatic cancer
Ignacio Garrido-Laguna, MD, PhD, MBA Garrido-Laguna (Huntsman Cancer Institute, University of Utah) – Targeting KRAS beyond G12C
Closing remarks: Alfredo Carrato (Hospital Ruber Internacional, Madrid).”
More posts featuring Nelson Dusetti on OncoDaily.